What is polypharmacy? A systematic review of definitions

Nashwa Masnoon, Sepehr Shakib, Lisa Kalisch-Ellett, Gillian E Caughey, Nashwa Masnoon, Sepehr Shakib, Lisa Kalisch-Ellett, Gillian E Caughey

Abstract

Background: Multimorbidity and the associated use of multiple medicines (polypharmacy), is common in the older population. Despite this, there is no consensus definition for polypharmacy. A systematic review was conducted to identify and summarise polypharmacy definitions in existing literature.

Methods: The reporting of this systematic review conforms to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist. MEDLINE (Ovid), EMBASE and Cochrane were systematically searched, as well as grey literature, to identify articles which defined the term polypharmacy (without any limits on the types of definitions) and were in English, published between 1st January 2000 and 30th May 2016. Definitions were categorised as i. numerical only (using the number of medications to define polypharmacy), ii. numerical with an associated duration of therapy or healthcare setting (such as during hospital stay) or iii. Descriptive (using a brief description to define polypharmacy).

Results: A total of 1156 articles were identified and 110 articles met the inclusion criteria. Articles not only defined polypharmacy but associated terms such as minor and major polypharmacy. As a result, a total of 138 definitions of polypharmacy and associated terms were obtained. There were 111 numerical only definitions (80.4% of all definitions), 15 numerical definitions which incorporated a duration of therapy or healthcare setting (10.9%) and 12 descriptive definitions (8.7%). The most commonly reported definition of polypharmacy was the numerical definition of five or more medications daily (n = 51, 46.4% of articles), with definitions ranging from two or more to 11 or more medicines. Only 6.4% of articles classified the distinction between appropriate and inappropriate polypharmacy, using descriptive definitions to make this distinction.

Conclusions: Polypharmacy definitions were variable. Numerical definitions of polypharmacy did not account for specific comorbidities present and make it difficult to assess safety and appropriateness of therapy in the clinical setting.

Keywords: Aged; Comorbidity; Inappropriate prescribing; Multimorbidity; Polypharmacy; Systematic review.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study selection flowchart according to PRISMA checklist

References

    1. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013:1–9.
    1. Roughead EE, Vitry AI, Caughey GE, Gilbert AL. Multimorbidity, care complexity and prescribing for the elderly. Aging Health. 2011;7(5):695–705. doi: 10.2217/ahe.11.64.
    1. Caughey GE, Ramsay EN, Vitry AI, Gilbert AL, Luszcz MA, Ryan P, et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Community Health. 2010;64(12):1036–1042. doi: 10.1136/jech.2009.088260.
    1. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–439. doi: 10.1016/j.arr.2011.03.003.
    1. World Health Organization . Global age-friendly cities project. 2016.
    1. Milton JC, Hill-Smith I, Jackson SHD. Prescribing for older people. BMJ. 2008;336(7644):606–609. doi: 10.1136/bmj.39503.424653.80.
    1. Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010;19(9):977–982. doi: 10.1002/pds.2009.
    1. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87(3):385–393. doi: 10.1016/j.diabres.2009.10.019.
    1. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. doi: 10.1517/14740338.2013.827660.
    1. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–389. doi: 10.2147/CIA.S2468.
    1. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187–195. doi: 10.1111/j.1365-2125.2006.02744.x.
    1. Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Reduction of high-risk Polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2005;25(11):1636–1645. doi: 10.1592/phco.2005.25.11.1636.
    1. Veehof LJG, Meyboom-De Jong B, Haaijer-Ruskamp FM. Polypharmacy in the elderly - a literature review. Eur J Gen Pract. 2000;6(3):98–106. doi: 10.3109/13814780009069956.
    1. Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: balancing evidence-based medicine against falls risk. Postgrad Med. 2015;127(3):330–337. doi: 10.1080/00325481.2014.996112.
    1. Alic A, Pranjic N, Ramic E. Polypharmacy and decreased cognitive abilities in elderly patients. Med Arh. 2011;65(2):102–105.
    1. Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11. doi: 10.3928/0098-9134-20050901-04.
    1. Garcia J, Vaz M, Poggi M. Estimated prevalence of contraindicated, severe and moderate interactions in ambulatory patients with polypharmacy in a healthcare provider in Uruguay. Clin Ther. 2015;1:145.
    1. Patton D, Hughes C, Cadogan CA, Francis J, Gormley GJ, Kerse N, et al. Using the theoretical domains framework (TDF) to explore barriers and facilitators to adherence to prescribed medicines in community-based older adults. Int J Pharm Pract. 2015;23:11–12.
    1. Trumic E, Pranjic N, Begic L, Becic F, Asceric M. Idiosyncratic adverse reactions of most frequent drug combinations longterm use among hospitalized patients with polypharmacy. Med Arh. 2012;66(4):243–248. doi: 10.5455/medarh.2012.66.243-248.
    1. Ziere G, Dieleman JP, Hofman A, Pols HAP, Van Der Cammen TJM, Stricker BHC. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61(2):218–223. doi: 10.1111/j.1365-2125.2005.02543.x.
    1. Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging. 2014;31(4):283–289. doi: 10.1007/s40266-014-0163-7.
    1. McMahon CG, Cahir CA, Kenny RA, Bennett K. Inappropriate prescribing in older fallers presenting to an Irish emergency department. Age Ageing. 2014;43(1):44–50. doi: 10.1093/ageing/aft114.
    1. Bahat G, Tufan F, Bahat Z, Tufan A, Aydin Y, Akpinar TS, et al. Comorbidities, polypharmacy, functionality and nutritional status in Turkish community-dwelling female elderly. Aging Clin Exp Res. 2014;26(3):255–259. doi: 10.1007/s40520-014-0229-8.
    1. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995. doi: 10.1016/j.jclinepi.2012.02.018.
    1. Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol. 2012;3(3):228–237. doi: 10.1016/j.jgo.2012.02.005.
    1. Rasu RS, Iqbal M, Hanifi SMA, Moula A, Hoque S, Rasheed S, et al. Level, pattern, and determinants of polypharmacy and inappropriate use of medications by village doctors in a rural area of Bangladesh. Clinicoecon Outcomes Res. 2014;6:515–521. doi: 10.2147/CEOR.S67424.
    1. Ahmed B, Nanji K, Mujeeb R, Patel MJ. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care Hospital in Karachi: a prospective cohort study. PLoS One. 2014;9(11):1–7. doi: 10.1371/journal.pone.0112133.
    1. Launay CP, De Decker L, Kabeshova A, Annweiler C, Beauchet O. Screening for older emergency department inpatients at risk of prolonged hospital stay: the brief geriatric assessment tool. PLoS One. 2014;9(10):1–10. doi: 10.1371/journal.pone.0110135.
    1. Haider SI, Ansari Z, Vaughan L, Matters H, Emerson E. Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability. Res Dev Disabil. 2014;35(11):3071–3080. doi: 10.1016/j.ridd.2014.07.060.
    1. Diez-Manglano J, Gimenez-Lopez M, Garces-Horna V, Sevil-Puras M, Castellar-Otin E, Gonzalez-Garcia P, et al. Excessive polypharmacy and survival in polypathological patients. Eur J Clin Pharmacol. 2015;71(6):733–739. doi: 10.1007/s00228-015-1837-8.
    1. Jiron M, Tapia M, Sandoval T, Palma D, Orellana S, Escobar L, et al. Potentially inappropriate medication among Chilean older inpatients: comparison between a 2012 beers criteria and STOPP. Pharmacoepidemiol Drug Saf. 2015;24:102–103.
    1. Jiron M, Herrada L, Rojas A, Lueiza A, Vega E, Buckel E, et al. Prevalence of potentially inappropriate medication prescribing among older adults in emergency Department in Chile. Pharmacoepidemiol Drug Saf. 2015;24:102.
    1. Fustinoni S, Renard D, Santos-Eggimann B, Seematter-Bagnoud L. Polypharmacy and associated factors among community-dwelling older persons in a Swiss canton. Clin Ther. 2015;37:39–40.
    1. Jodar-Sanchez F, Malet-Larrea A, Martin JJ, Garcia-Mochon L. Lopez del Amo MP, Martinez-Martinez F, et al. cost-utility analysis of a medication review with follow-up Service for Older Adults with Polypharmacy in community pharmacies in Spain: the conSIGUE program. PharmacoEconomics. 2015;33(6):599–610. doi: 10.1007/s40273-015-0270-2.
    1. Yang M, Lu J, Hao Q, Luo L, Dong B. Does residing in urban or rural areas affect the incidence of polypharmacy among older adults in western China? Arch Gerontol Geriatr. 2015;60(2):328–333. doi: 10.1016/j.archger.2014.11.004.
    1. Nguyen OK, Makam AN, Halm E. Use of safety net clinics for primary care among insured individuals in the United States: NAMCS 2006-2010. J Gen Intern Med. 2015;30:295. doi: 10.1007/s11606-014-2969-8.
    1. Jensen LD, Andersen O, Hallin M, Petersen J. Potentially inappropriate medication related to weakness in older acute medical patients. Int J Clin Pharm. 2014;36(3):570–580. doi: 10.1007/s11096-014-9940-y.
    1. Mastromarino V, Casenghi M, Testa M, Gabriele E, Coluccia R, Rubattu S, et al. Polypharmacy in heart failure patients. Curr Heart Fail Rep. 2014;11(2):212–219. doi: 10.1007/s11897-014-0186-8.
    1. Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. Am J Alzheimers Dis Other Demen. 2011;26(8):606–615. doi: 10.1177/1533317511432734.
    1. Lai SW, Su LT, Lin CH, Tsai CH, Sung FC, Hsieh DP. Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: a population-based study. Psychogeriatrics. 2011;11(3):150–156. doi: 10.1111/j.1479-8301.2011.00369.x.
    1. Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging. 2011;28(7):547–560. doi: 10.2165/11592000-000000000-00000.
    1. Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507–519. doi: 10.1007/s00228-010-0977-0.
    1. Ariza G, Blanco E, Leon M, Gonzalez-Correa JA. Polipharmacy in primary care. Eur Geriatr Med. 2011;2:172. doi: 10.1016/j.eurger.2011.04.004.
    1. Cronin H, O'Regan C, Savva G, Richardson K, Donoghue O, Kenny RA. Polypharmacy and falls in older Irish adults. Ir J Med Sci. 2011;180:S355. doi: 10.1007/s11845-011-0689-1.
    1. Nomura K, Mendelsohn AB, Kusama M, Igarashi A, Akazawa M. Drug use patterns and predictors of polypharmacy among elderly, community-residing persons in hiroshima. Japan Pharmacoepidemiol Drug Saf. 2011;20:301–302.
    1. Blanco-Reina E, Ariza-Zafra G, Gonzalez-Correa JA, Leon-Ortiz M. Polypharmacy and pattern of medication use among the elderly. Basic Clin Pharmacol Toxicol. 2011;109:67. doi: 10.1111/j.1742-7843.2011.00774.x.
    1. Heuberger R. Polypharmacy and food-drug interactions among older persons: a review. J Nutr Gerontol Geriatr. 2012;31(4):325–403. doi: 10.1080/21551197.2012.729902.
    1. Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region. Italy. Drugs Aging. 2010;27(12):1019–1028. doi: 10.2165/11584990-000000000-00000.
    1. Slabaugh SL, Maio V, Abouzaid S, Templin M. Prevalence and predictors of polypharmacy amongst elderly patients: a population-based cohort study. Value Health. 2010;13(3):181. doi: 10.1016/S1098-3015(10)72883-7.
    1. Grimmsmann T, Himmel W. Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiol Drug Saf. 2009;18(12):1206–1213. doi: 10.1002/pds.1841.
    1. Lapi F, Pozzi C, Mazzaglia G, Ungar A, Fumagalli S, Marchionni N, et al. Epidemiology of suboptimal prescribing in older, community dwellers: a two-wave, population-based survey in dicomano. Italy Drugs Aging. 2009;26(12):1029–1038. doi: 10.2165/11319390-000000000-00000.
    1. Chan DC, Hao YT, Wu SC. Characteristics of outpatient prescriptions for frail Taiwanese elders with long-term care needs. Pharmacoepidemiol Drug Saf. 2009;18(4):327–334. doi: 10.1002/pds.1712.
    1. Haider SI, Johnell K, Thorslund M, Fastbom J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged >77 years in Sweden. Clin Ther. 2008;30(2):419–427. doi: 10.1016/j.clinthera.2008.02.010.
    1. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA, Group OS Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130–133. doi: 10.1111/j.1365-2125.2007.02961.x.
    1. Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, et al. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014;22(7):1727–1734. doi: 10.1007/s00520-014-2171-x.
    1. Dhikav V, Sethi M, Singhal AK, Anand KS. Polypharmacy and use of potentially inappropriate medications in patients with dementia and mild cognitive impairment. Asian Journal of Pharmaceutical and Clinical Research. 2014;7(2):218–220.
    1. Van Daalen AM, Van Leeuwen JA, Spruit-Van Eijk M, Achterberg WP. Polypharmacy as predictive factor for successful discharge in geriatric rehabilitation of stroke patients admitted to skilled nursing facilities. Eur Geriatr Med. 2014;5:242–243. doi: 10.1016/S1878-7649(14)70670-9.
    1. Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Hersh L, Chapman A. The prevalence of polypharmacy (PP) and potentially inappropriate medication (PIM) use in senior adult oncology (SAO) patients at an urban academic medical center. J Oncol Pharm Pract. 2014;1:5.
    1. Sheehan K, O'Shea D, Crowe M, Hughes G, Browne J. Potentially inappropriate medications in older hospitalised patients. Ir J Med Sci. 2014;1:328.
    1. Shimizu K, Ishii S, Tanaka T, Shibasaki K, Akishita M, Iijima K. Use of potentially inappropriate medication and polypharmacy in community-dwelling japanese elderly population from the kashiwa study. J Am Geriatr Soc. 2014;62:249–250.
    1. Sato I, Akazawa M. Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study. Drug Healthc Patient Saf. 2013;5(1):143–150.
    1. Koper D, Kamenski G, Flamm M, Bohmdorfer B, Sonnichsen A. Frequency of medication errors in primary care patients with polypharmacy. Fam Pract. 2013;30(3):313–319. doi: 10.1093/fampra/cms070.
    1. Lin HF, Lai SW, Liao KF, Muo CH, Hsientang Hsieh DP. Synergistic interaction between alcoholism and polypharmacy on the risk of falls in the elderly. Int J Gerontol. 2013;7(2):122–123. doi: 10.1016/j.ijge.2012.07.010.
    1. Pal A, Babbott S, Wilkinson ST. Can the targeted use of a discharge pharmacist significantly decrease 30-day readmissions? Hosp Pharm. 2013;48(5):380–388. doi: 10.1310/hpj4805-380.
    1. Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure-a register-based study in Sweden 2005-2009. Health Policy. 2013;109(2):166–174. doi: 10.1016/j.healthpol.2012.09.005.
    1. Blanco E, Ariza G, Ocana R, Leon M. Potential prescribing omissions vs. Polipharmacy among elderly patients Basic Clin Pharmacol Toxicol. 2013;113:10.
    1. Costa JO, Moura CS, Acurcio FA, Guimaraes MDC. Prevalence and correlates of polypharmacy among men and women with mental illness in Brazil: Pessoas project. Pharmacoepidemiol Drug Saf. 2013;22:461.
    1. Gonzalez-Muniz V, Soler-Rodenas A, Gil Manez E, Gea Rodriguez E. Spreading results of a previous start/stop study in older institutionalized residents: Impact on the prevalence of polypharmacy. Int J Clin Pharm. 2013;2:961.
    1. Davila Barboza YR, Azana Fernandez EH. Polypharmacy in elderly patients: influence of hospitalization. Eur Geriatr Med. 2013;4:S189–SS90. doi: 10.1016/j.eurger.2013.07.633.
    1. O'Dwyer M, Peklar J, McCarron M, McCallion P, Henman M. Prevalence, patterns and factors associated with polypharmacy and excessive polypharmacy in an ageing population with intellectual disability in Ireland. Ir J Med Sci. 2013;182:210.
    1. Carvalho MF, Romano-Lieber NS, Bergsten-Mendes G, Secoli SR, Ribeiro E, Lebrao ML, et al. Polypharmacy among the elderly in the city of Sao Paulo, Brazil - SABE study. Rev Bras Epidemiol. 2012;15(4):817–827. doi: 10.1590/S1415-790X2012000400013.
    1. Skov J, Bladbjerg EM, Sidelmann J, Vamosi M, Jespersen J. Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic. Eur J Clin Pharmacol. 2011;67(11):1169–1174. doi: 10.1007/s00228-011-1045-0.
    1. Pugh MJ, Palmer RF, Parchman ML, Mortensen E, Markides K, Espino DV. Association of suboptimal prescribing and change in lower extremity physical function over time. Gerontology. 2007;53(6):445–453. doi: 10.1159/000119460.
    1. Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One. 2014;9 (6) (e98043):1–7.
    1. Puvanendran R, Mamun K, Lim KH. Polypharmacy and unneccessary medication use in elderly patients discharged from acute hospitals to community hospital. Proceedings of Singapore Healthcare. 2011;20:167.
    1. Golchin N, Frank S, Isham L, Vince A, Meropol SB. Polypharmacy in the elderly. Pharmacoepidemiol Drug Saf. 2011;20:S296–S2S7.
    1. Joaquim JJ, Campos MC. Drug use and knowledge in a elderly polimedicated Portuguese population. Basic Clin Pharmacol Toxicol. 2011;109:143.
    1. Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrol. 2012;13(1):1–7. doi: 10.1186/1471-2369-13-96.
    1. Chong J, Ang S. Polypharmacy in hospitalized older adults. J Am Geriatr Soc. 2010;58:162.
    1. Mohammed S, Arabi A, El-Menyar A, Abdulkarim S, Awaisu A, Alqahtani A, et al. Impact of polypharmacy on adherence to evidence-based medications in patients who underwent percutenous coronary intervention. J Am Coll Cardiol. 2014;2:3.
    1. Best O, Gnjidic D, Hilmer SN, Naganathan V, McLachlan AJ. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J. 2013;43(8):912–918. doi: 10.1111/imj.12203.
    1. Kuzuya M, Masuda Y, Hirakawa Y, Iwata M, Enoki H, Hasegawa J, et al. Underuse of medications for chronic diseases in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc. 2006;54(4):598–605. doi: 10.1111/j.1532-5415.2006.00659.x.
    1. Schuler J, Duckelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr. 2008;120(23–24):733–741. doi: 10.1007/s00508-008-1089-z.
    1. Hoffman J, Gleiberman S, Stern D, Osterweil D. Impact of a pharmacist in a specialized ambulatory care geriatric setting. J Am Geriatr Soc. 2014;62:139.
    1. Dorks M, Herget-Rosenthal S, Schmiemann G, Hoffmann F. Polypharmacy and renal failure in nursing home residents: results of the inappropriate medication in patients with renal insufficiency in nursing homes (IMREN) study. Drugs Aging. 2016;33(1):45–51. doi: 10.1007/s40266-015-0333-2.
    1. Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637–646. doi: 10.1002/pds.3772.
    1. Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453–1459. doi: 10.1200/JCO.2014.58.7550.
    1. Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 national nursing home survey. Am J Geriatr Pharmacother. 2010;8(1):63–72. doi: 10.1016/j.amjopharm.2010.01.001.
    1. Onder G, Liperoti R, Foebel A, Fialova D, Topinkova E, Van der Roest HG, et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the shelter study. J Am Med Dir Assoc. 2013;14(6):450.7–45012. doi: 10.1016/j.jamda.2013.03.014.
    1. Teymoorian SS, Pal A, Hayley D. Risk factors for 30-day hospital readmissions in older adults. J Am Geriatr Soc. 2011;59:S188. doi: 10.1111/j.1532-5415.2011.03376.x.
    1. Barnett K, McCowan C, Evans JM, Gillespie ND, Davey PG, Fahey T. Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community. BMJ Qual Saf. 2011;20(3):275–281. doi: 10.1136/bmjqs.2009.039818.
    1. Jorgensen TL, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol. 2012;3(1):33–40. doi: 10.1016/j.jgo.2011.09.001.
    1. Nagaraju B, Padmavathi GV, Dattathreya G. Prevalence and assessment of polypharmacy in Sri Devraj URS medical college & hospital. Kolar Int J Pharm Pharm Sci. 2012;4(1):488–493.
    1. Borja-Oliveira CR, Lotti L. Polypharmacy and inappropriate prescribing in institutionalized elderly. J Am Geriatr Soc. 2015;63:228.
    1. Lu J, Yang M, Luo L, Hao Q, Dong B. Polypharmacy among nonagenarians/centenarians in rural China. Intern Med J. 2014;Part A. 44(12):1193-1199.
    1. Yu H, Foley SE, Crocker JA, Tuskey AG, Behm BW. Polypharmacy in patients with crohn's disease. Gastroenterology. 2014;146:445–6.
    1. Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther. 2005;21(10):1211–1216. doi: 10.1111/j.1365-2036.2005.02429.x.
    1. Fano V, Chini F, Pezzotti P, Bontempi K, Rossi A. Estimating prevalence of polypharmacy using data from a health administrative database: A comparison of results obtained with different algorithms. Eur J Epidemiol. 2013;1:1–7.
    1. Housley BC, Stawicki SP, Evans DC, Jones C. Comorbidity-polypharmacy score predicts readmission in older trauma patients. J Surg Res. 2015;199(1):237–243. doi: 10.1016/j.jss.2015.05.014.
    1. Ferreira AR, Passos J, Martins S, Fernandes L. Comorbidity and polypharmacy in residential care and community-dwelling elderly in Portugal. Eur Neuropsychopharmacol. 2015;25:S595. doi: 10.1016/S0924-977X(15)30837-3.
    1. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17(3):261–267. doi: 10.1093/fampra/17.3.261.
    1. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521–528. doi: 10.1038/clpt.2011.258.
    1. Jiron M, Pate V, Hanson LC, Funk MJ, Sturmer T. Prevalence and determinants of potentially inappropriate medication prescribing among older US adults according to STOPP criteria. Pharmacoepidemiol Drug Saf. 2015;24:105.
    1. Narayan SW, Nishtala PS. Associations of potentially inappropriate medicine use with fall-related Hospitalisations and primary care visits in older new Zealanders: a population-level study using the updated 2012 beers criteria. Drugs Real World Outcomes. 2015;2(2):137–141. doi: 10.1007/s40801-015-0020-y.
    1. Kann IC, Lundqvist C, Luras H. Polypharmacy among the elderly in a list-patient system. Drugs Real World Outcomes. 2015;2(3):193–198. doi: 10.1007/s40801-015-0036-3.
    1. Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597–602. doi: 10.1016/j.ejim.2011.08.029.
    1. Chan DC, Hao YT, Wu SC. Polypharmacy among disabled taiwanese elderly: a longitudinal observational study. Drugs Aging. 2009;26(4):345–354. doi: 10.2165/00002512-200926040-00005.
    1. Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older new zealanders over a 9-year period: 2005-2013. Gerontology. 2015;61(3):195–202. doi: 10.1159/000368191.
    1. Vetrano DL, Landi F, De Buyser SL, Carfi A, Zuccala G, Petrovic M, et al. Predictors of length of hospital stay among older adults admitted to acute care wards: a multicentre observational study. Eur J Intern Med. 2014;25(1):56–62. doi: 10.1016/j.ejim.2013.08.709.
    1. Sganga F, Vetrano DL, Volpato S, Cherubini A, Ruggiero C, Corsonello A, et al. Physical performance measures and polypharmacy among hospitalized older adults: results from the crime study. J Nutr Health Aging. 2014;18(6):616–621. doi: 10.1007/s12603-014-0029-z.
    1. Franchi C, Cartabia M, Risso P, Mari D, Tettamanti M, Parabiaghi A, et al. Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-elderly project. Eur J Clin Pharmacol. 2013;69(7):1477–1483. doi: 10.1007/s00228-013-1495-7.
    1. Gillette C, Prunty L, Wolcott J, Broedel-Zaugg K. A new lexicon for polypharmacy: implications for research, practice, and education. Res Social Adm Pharm. 2015;11(3):468–471. doi: 10.1016/j.sapharm.2014.08.010.
    1. Filkova M, Carvalho J, Norton S, Scott DL, Mant T, Cope AP, et al. Polypharmacy is a predictor of hospitalisation in patients with rheumatoid arthritis. American College of Rheumatology and Association of Rheumatology Health Professionals Annual Scientific Meeting; San Francisco, CA 2015.
    1. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–522. doi: 10.1634/theoncologist.2009-0290.
    1. Medeiros-Souza P, dos Santos-Neto LL, Kusano LTE, Pereira MG. Diagnosis and control of polypharmacy in the elderly. Rev Saude Publica. 2007;41(6):1049–1053. doi: 10.1590/S0034-89102006005000050.
    1. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123–132. doi: 10.1111/j.1041-2972.2005.0020.x.
    1. Cadogan C, Ryan C, Gormley G, Passmore P, Francis J, Kerse N, et al. Dispensing appropriate polypharmacy to older people in primary care: a qualitative, theory-based study of community pharmacists' perceptions and experiences. Int J Pharm Pract. 2015;23:32. doi: 10.1111/ijpp.12182.
    1. Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Crit Care Nurs Q. 2008;31(1):40–45. doi: 10.1097/01.CNQ.0000306395.86905.8b.
    1. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20(11):817–832. doi: 10.2165/00002512-200320110-00003.
    1. Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey on Polypharmacy and use of inappropriate medications. Toxicol Int. 2012;19(1):68–73. doi: 10.4103/0971-6580.94506.
    1. Hanger C. Polypharmacy in primary care: managing a clinical conundrum. Best Practice Journal. 2014;64
    1. Cadogan CA, Ryan C, Hughes CM. Appropriate Polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39(2):109–116. doi: 10.1007/s40264-015-0378-5.
    1. Steinman MA. Polypharmacy-time to get beyond numbers. JAMA Intern Med. 2016;176(4):482–483. doi: 10.1001/jamainternmed.2015.8597.
    1. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834. doi: 10.1001/jamainternmed.2015.0324.
    1. Gorard DA. Escalating polypharmacy. QJM. 2006;99(11):797–800. doi: 10.1093/qjmed/hcl109.
    1. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update Arch Intern Med. 1997;157(14):1531–1536. doi: 10.1001/archinte.1997.00440350031003.
    1. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean J, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a us consensus panel of experts. Arch Intern Med. 2003;163(22):2716–2724. doi: 10.1001/archinte.163.22.2716.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다